Başkent University Joins Clinerion’s Patient Recruitment System Platform
Basel, August 2, 2017 – BaÅkent University’s hospital cluster is joining the Patient Recruitment System platform, giving their 4.5 M patients access to treatments and therapies offered by clinical research.
BaÅkent University has its headquarters in Ankara, Turkey. With over 1,500 beds, the university has hospitals in seven further locations throughout Turkey. There are six general hospitals, in Ankara, Adana, Alanya, Ä°stanbul, Konya, and Ä°zmir; and four specialist centers: the AyaÅ Physical Therapy and Rehabilitation Center, the Yapracık Psico-Social Rehabilitation Center, Umitkoy Polyclinic, and another eight geographically distributed dialysis centers.
With this move, BaÅkent University will gain the advantages of partnership with the Patient Recruitment System (PRS) platform: visibility to sponsors making trial siting decisions, increased speed and effectiveness in recruitment, increased efficiency in matching studies to the hospital’s own patient population. Sites can also make use of PRS, internally, for academic trials with the assurance of compliance to hospital-level data access permissions.
The addition of BaÅkent University extends Clinerion’s coverage, geographically, throughout Turkey. It also extends the PRS network’s treatment capabilities with the addition of specialist centers for physical and psychological rehabilitation, and dialysis.
“BaÅkent University is proud to be the premier private medical research institution in Turkey and we are happy that partnership with Clinerion will also allow us to increase participation in the international research and development of the next generation of medical treatments,” says Professor Haldun MüderrisoÄlu, Dean of the Medical Faculty at BaÅkent University. “This will also allow us to offer more treatment options for our patients.”
“We are very happy to have the best private university hospital group in Turkey in PRS,” says Ulf Claesson, CEO of Clinerion. “We have been expanding around the world, but BaÅkent allows us to extend our presence throughout Turkey, giving us near-complete coverage of the country.”
Contact details for Clinerion Turkey:
BariÅ ErdoÄan, PhD
Head of EEMEA Region
Clinerion Turkey Teknoloji Arastirma Ltd. Sti.
Uphill Towers A-87 Batı, AtaÅehir, Ä°stanbul, Türkiye
T +90 216 688 00 86
Clinerion website: www.clinerion.com
Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem
For more information, please contact:
Le Vin Chin
Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
